Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation

Doxorubicin (Dox) is a commonly used anthracycline chemotherapy with a side effect of cardiotoxicity, which may increase the risk of heart failure for cancer patients. Although various studies have demonstrated the cardioprotective property of dapagliflozin (DAPA), a sodium-glucose cotransporter 2 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Pei-Ling, Chu, Pei-Ming, Cheng, Hui-Ching, Huang, Yu-Ting, Chou, Wan-Ching, Tsai, Kun-Ling, Chan, Shih-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456438/
https://www.ncbi.nlm.nih.gov/pubmed/36077544
http://dx.doi.org/10.3390/ijms231710146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456438/
https://www.ncbi.nlm.nih.gov/pubmed/36077544
http://dx.doi.org/10.3390/ijms231710146

Ejemplares similares